ICON plc (ICLR) – Press Releases
-
ICON Reports First Quarter 2024 Results
-
ICON Announces CFO Transition
-
ICON plc Schedules First Quarter 2024 Earnings Conference Call
-
ICON plc to Present at Upcoming Investor Conferences
-
ICON Reports Fourth Quarter and Full Year 2023 Results
-
ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call
-
New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment
-
ICON Issues Financial Guidance for Full Year 2024
-
Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON
-
ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
ICON Wins Industry Accolades from TIME Magazine, Forbes and Financial Times in Second Half of 2023
-
ICON Secures Upgraded Credit Rating from Moody’s Investors Service
-
ICON plc to Present at Upcoming Investor Conferences
-
ICON Reports Third Quarter 2023 Results
-
ICON Secures Upgraded Credit Rating from S&P Global Ratings
-
ICON plc Schedules Third Quarter 2023 Earnings Conference Call
-
ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution
-
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
-
ICON plc to Present at the Baird Global Healthcare Conference
-
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
-
ICON Reports Second Quarter 2023 Results
-
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
-
ICON plc Schedules Second Quarter 2023 Earnings Conference Call
-
ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform
-
ICON plc Set to Join Russell 3000® Index
-
ICON plc to Attend Upcoming Investor Conferences
-
ICON releases its 2022 ICON Cares ESG Report
-
ICON Reports First Quarter 2023 Results
-
ICON plc Schedules First Quarter 2023 Earnings Conference Call
-
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
-
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
-
ICON plc to Present at Upcoming Investor Conferences
-
ICON Reports Fourth Quarter and Full Year 2022 Results
-
ICON plc Schedules Fourth Quarter 2022 Earnings Conference Call
-
ICON Issues Financial Guidance for Full Year 2023
-
ICON plc to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others
-
ICON plc to Present at the 2022 Evercore ISI HealthCONx Conference
-
ICON Reports Third Quarter 2022 Results
-
ICON selected by BARDA to conduct anthrax vaccine clinical trial
-
ICON plc Schedules Third Quarter 2022 Earnings Conference Call
-
ICON Releases its 2021 ESG Report
-
ICON plc to Present at the 2022 Wells Fargo Healthcare Conference
-
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
-
ICON Reports Second Quarter 2022 Results
-
ICON plc Schedules Second Quarter 2022 Earnings Conference Call
-
ICON plc to present at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference
-
ICON Named Business & Finance Company of the Year and One of Forbes’ Best Employers for Diversity
-
ICON plc to present at the BofA Securities 2022 Healthcare Conference
-
ICON Reports First Quarter 2022 Results
Back to ICLR Stock Lookup
